A further understanding on the CCR5-mediated HIV-1 entry and identifying new regions that participate in this process should contribute to a new vaccine design aiming to elicit antibodies that potently block HIV-1 infection without any interference on physiological function of CCR5. The gene discussed is CCR5; the disease is HIV-1 infection.